Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

46.78
+0.16000.34%
Post-market: 46.780.00000.00%17:41 EDT
Volume:3.68M
Turnover:174.09M
Market Cap:112.55B
PE:12.45
High:47.83
Open:47.50
Low:46.76
Close:46.62
52wk High:56.00
52wk Low:43.32
Shares:2.41B
Float Shares:2.20B
Volume Ratio:1.29
T/O Rate:0.17%
Dividend:2.27
Dividend Rate:4.86%
EPS(TTM):3.76
EPS(LYR):3.76
ROE:6.66%
ROA:4.65%
PB:1.37
PE(LYR):12.45

Loading ...

European Stocks Mostly Lower in Tuesday Trading; UK Regulator Seeks Views on Apple, Google Competition Commitments

MT Newswires Live
·
Feb 11

Sanofi Obtains FDA Breakthrough Therapy Designation for Anemia Treatment

MT Newswires Live
·
Feb 09

OneSpaWorld to replace Dynavax in S&P 600 at open on 2/10

TIPRANKS
·
Feb 05

Sanofi's Rezurock Expands Provincial Access in Canada

MT Newswires Live
·
Feb 04

Sanofi Launches $1.18 Billion Share Buyback Program

MT Newswires Live
·
Feb 03

“Signal of Strength”: Sanofi (SNY) Launches €1 Billion Stock Buyback for 2026

TIPRANKS
·
Feb 03

Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says

MT Newswires Live
·
Feb 03

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Precious Metals Downturn

MT Newswires Live
·
Feb 02

Sanofi Found by UK Regulator in Breach of Pharmaceutical Industry Code

MT Newswires Live
·
Feb 02

Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials

Benzinga_recent_news
·
Feb 02

Sanofi Says Venglustat Meets Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease

MT Newswires Live
·
Feb 02

European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Up for Week

MT Newswires Live
·
Jan 31

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Benzinga
·
Jan 30

Sanofi Says EU Conditional Approval Recommended for Rezurock in Graft-versus-Host Disease

MT Newswires Live
·
Jan 30

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Jan 30

Sector Update: Health Care

MT Newswires Live
·
Jan 29

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Dow Jones
·
Jan 29

Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks

Benzinga
·
Jan 29

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

Dow Jones
·
Jan 29

Sanofi Eyes High Single-Digit Sales Growth in 2026, Dupixent Patent Expiry Looms

Reuters
·
Jan 29